Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Provention Bio Inc (NQ: PRVB )

24.10 -0.11 (-0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,813,033
Open 24.17
Bid (Size) 24.11 (4)
Ask (Size) 24.26 (5)
Prev. Close 24.21
Today's Range 24.04 - 24.30
52wk Range 3.185 - 24.30
Shares Outstanding 94,780,874
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
From Kahn Swick & Foti, LLC
Via Business Wire
Is Sanofi Stock a Buy Now?
The pharma giant has outperformed the broader market over the past 12 months. 
Via The Motley Fool

Performance

YTD
+149.22%
+149.22%
1 Month
+187.25%
+187.25%
3 Month
+128.00%
+128.00%
6 Month
+435.56%
+435.56%
1 Year
+229.23%
+229.23%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Provention Bio's Earnings Outlook
Via Benzinga
4 Analysts Have This to Say About Provention Bio
Via Benzinga
Provention Bio, Inc. (NASDAQ: PRVB) Making Surprising Moves in Monday Session
Via Investor Brand Network
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Via Benzinga
Top 5 Health Care Stocks That May Crash In March
Via Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
Why Provention Bio Stock Skyrocketed 256% This Week
Via The Motley Fool
Why Shares of MacroGenics Climbed Thursday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
From Kahn Swick & Foti, LLC
Via Business Wire
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Via The Motley Fool
Nasdaq Up 150 Points; Gold Rises Over 2%
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Via Spotlight Growth
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps 300 Points; Crude Oil Down 1%
Via Benzinga
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
US Stocks Mostly Higher; Dow Rises 75 Points
Via Benzinga
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.